Back to search results

Xeomin® and Walking After Stroke

This study is looking at whether injections of Xeomin® (a medication) into the arm can improve walking ability and quality of life for adults who have weakness on one side of their body (hemiparesis) and muscle stiffness (spasticity) after a stroke. Researchers want to see if these injections help with tasks like walking and getting up and moving around. You might be able to join if you are 18 to 79 years old, have hemiparesis and spasticity from a stroke, and can walk at least 10 meters without help. The study will measure changes in your walking speed and ability using specific tests. The current status of this study is unclear.

Study design
This is a pilot study with 20 participants. It uses a one-group design where participants are tested before and after receiving Xeomin® injections.
What's involved
You will have tests before receiving Xeomin® injections into your upper arm, and again 4-6 weeks later. There will also be a phone call about 12 weeks after the injection to check for side effects and how long the treatment's effects last.
Compensation
Not stated in the trial record.
Follow-up
Participants will be contacted for an end-of-study visit via telephone approximately 12 weeks after the Xeomin® injection.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04908423

Xeomin® and Gait Related Mobility After Stroke

Recruiting
PHASE4Ages 18–79InterventionalTreatment
Wake Forest University Health Sciences
~20 participants
Updated 2025-11-25 on ClinicalTrials.gov
What's tested:Xeomin®

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in Instrumented Timed Up and Go test time
Measured over Baseline and 4-6 weeks after Xeomin injection

Conditions

Stroke

Explore related trials

Stroke

NCT04908423

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Carolinas Rehabilitation

    Charlotte, North Carolinastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Mark A Hirsch, PhD · PRINCIPAL_INVESTIGATOR · Wake Forest University Health Sciences

Who to contact

Mark A Hirsch, PhD
[email protected]
704-355-7673
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Diagnosis of hemiparesis and spasticity secondary to stroke with upper and lower limb spasticity and unilateral motor and/or sensory deficit
No prior surgery to the lower limb
Able to walk at least 10 meters without physical assistance from another person and without an assistive device
Toe- ground clearance during swing phase without assistive device or orthoses
No treatment with botulinum toxin within the past 4 months

Exclusion

Passive range of motion at either the ankle, knee, or elbow joint less than 30 degrees
Participants with uncorrected hearing impairment
Weight bearing restrictions due to concurrent orthopedic injuries that would make ambulating with or without an assistive device unsafe
Speech language expression deficit (e.g., aphasia)
Absence of proprioception upon neurologic examination
Presence of fixed contractures in the upper or lower extremities not correctable to neutral
Other confounding neurological diagnoses or active acute illness (cancer, Parkinson's disease, multiple sclerosis)

What this trial measures

  • Change in Instrumented Timed Up and Go test timeBaseline and 4-6 weeks after Xeomin injection

    Subjects arise from a chair, walk at their normal speed, turn around right after passing the tape at the end of the pathway, return to the chair, turn around and sit down. Subjects will be fitted with a , single Attitude and heading reference system (AHRS) sensor fixed on the manubrium inferior to the interclavicular notch in a chest-mounted pack. The AHRS is a wireless-telemetry, 10-parameter unit which includes a tri-axial accelerometer, a tri-axial gyroscope, a tri-axial magnetometer and an onboard temperature sensor.